Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 Deletion Treated With Eculizumab

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos et al. · The Lancet · 2020 · 422 citations

Medicine, Pharmacology, Pharmacotherapy +14

Deletion of Complement Factor H–Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic Syndrome

Peter F. Zipfel, Matthew Edey, Stefan Heinen et al. · PLoS Genetics · 2007 · 324 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells

Aldo M. Roccaro, Teru Hideshima, Noopur Raje et al. · Cancer Research · 2006 · 285 citations

Medicine, Oncology, Pharmacology +17